Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Sanofi
3-year registry of real-world use of DUPIXENT® for asthma in patients age 12 and over
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to comply with the required clinic visits, study procedures and assessments
Able to understand and complete study-related questionnaires
Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required
Initiating treatment with DUPIXENT® for a primary indication of asthma according to the country-specific prescribing information
You may not be if
Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments.
